Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cellectar Biosciences, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CLRB
Nasdaq
2830
www.cellectar.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cellectar Biosciences, Inc.
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Feb 5th, 2025 1:05 pm
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
- Jan 12th, 2025 11:00 pm
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
- Dec 11th, 2024 4:25 pm
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
- Dec 10th, 2024 10:00 pm
Q3 2024 Cellectar Biosciences Inc Earnings Call
- Nov 19th, 2024 6:39 am
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
- Nov 18th, 2024 12:05 pm
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
- Nov 14th, 2024 1:05 pm
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
- Nov 12th, 2024 1:05 pm
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
- Nov 11th, 2024 9:05 pm
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
- Nov 7th, 2024 11:40 am
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
- Nov 1st, 2024 9:00 pm
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
- Aug 30th, 2024 5:40 pm
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
- Aug 26th, 2024 10:40 am
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
- Aug 23rd, 2024 9:00 pm
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update
- Aug 13th, 2024 10:40 am
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
- Aug 8th, 2024 9:15 pm
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
- Aug 8th, 2024 8:05 pm
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
- Jul 23rd, 2024 10:40 am
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
- Jul 22nd, 2024 10:40 am
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
- Jun 27th, 2024 10:40 am
Scroll